Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
International Waldenstrom's Macroglobulinemia Foundation (IWMF) 2018 Forum
May 18 - 20, 2018; Rosemont, Illinois
May 18 - 20, 2018Rosemont, Illinois
IWMF 2018New Drugs Poised to Expand Treatment Horizons in WMNew drug combinations and pathways continue to be mined in an effort to expand treatment horizons for control of a rare lymphoma and extend quality of life for patients over many years to come.
Medscape Medical News, May 25, 2018
IWMF 2018Patience Needed: WM Is Incurable, but Survival Is LongManagement of the rare lymphoma Waldenstrom's macroglobulinemia (WM) takes patience and practice to maximize longevity and keep symptoms at bay over the long haul.
Ibrutinib Approved in US for Rare LymphomaThis is the first drug ever to be approved for the treatment of Waldenstrom's macroglobulinemia since the disease was described
70 years ago.
